

**Systemic Anti Cancer Treatment Protocol**

**Triptorelin  
Urology**

**PROTOCOL REF: MPHATRIUR  
(Version No: 1.0)**

**Approved for use in:**

- Treatment of locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration
- Treatment of metastatic prostate cancer
- Adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer
- Neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer
- Adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression.

**Dosage:**

Drug	Dosage	Route	Frequency
Triptorelin	3mg	IM	Every 28 days

Or

Drug	Dosage	Route	Frequency
Triptorelin	11.25mg	IM	Every 3 months

Or

Drug	Dosage	Route	Frequency
Triptorelin	22.5mg	IM	Every 6 months

**Supportive Treatments:**

N/A

Note:

Androgen deprivation can prolong QT interval, therefore caution should be exercised when prescribing for patients taking medication that may also prolong QT.

**Extravasation risk:**

N/A

**Administration:**

The suspension for injection must be reconstituted using an aseptic technique and only using the ampoule of solvent for injection.

The solvent should be drawn into the syringe provided using the reconstitution needle (20 G, without safety device) and transferred to the vial containing the powder. The suspension should be reconstituted by swirling the vial gently from side to side for long enough until a homogeneous, milky suspension is formed. Do not invert the vial.

It is important to check there is no unsuspended powder in the vial. The suspension obtained should then be drawn back into the syringe, without inverting the vial. The reconstitution needle should then be changed and the injection needle (20 G, with safety device) used to administer the product.

As the product is a suspension, the injection should be administered immediately after reconstitution to prevent precipitation.

Issue Date: September 2017 Review Date: September 2020	Page 2 of 3	Protocol reference: MPHATRIUR
Author: Richard Allen	Authorised by: Dr I Syndikus	Version No: 1.0

## Main toxicities

<b>Haematological</b>	Thrombocytopenia
<b>Psychiatric disorder</b>	Libido decreased/ loss, depression
<b>Gastrointestinal</b>	Dry mouth, nausea, abdominal pain, constipation, diarrhoea
<b>Cardiac disorders</b>	Palpitations
<b>Vascular disorders</b>	Hot flush, hypertension
<b>Additional side effects</b>	Back pain, musculoskeletal pain, erectile dysfunction, paraesthesia in lower limbs

## Investigations and Treatment Plan:

	Pre	C1	Ongoing
Medical Assessment	X		As clinically indicated
Nursing Assessment		X	Every cycle
U&E & LFTs	X	X	At medical review appointments as clinically indicated
PSA	X	X	Every cycle
CT scan	X		As clinically indicated
Informed Consent	X		
PS recorded	X	X	Every Cycle
Toxicities documented	X	X	Every Cycle
Weight recorded	X	X	Every cycle

## References:

Triptorelin, Summary of Product Characteristics. Ipsen Ltd 29/12/1994. Available from [www.medicines.org.uk/emc/medicine](http://www.medicines.org.uk/emc/medicine). Last updated 13/09/2001.

<https://www.nice.org.uk/advice/esnm30/chapter/Product-overview>

Issue Date: September 2017 Review Date: September 2020	Page 3 of 3	Protocol reference: MPHATRIUR
Author: Richard Allen	Authorised by: Dr I Syndikus	Version No: 1.0